Clinical Takeaway
People with PTSD and co-occurring substance use disorders who also use cannabis can still benefit meaningfully from trauma-focused treatments. Cannabis use does not appear to prevent or significantly undermine the effectiveness of evidence-based PTSD interventions in this population.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis directly addresses a critical clinical gap by examining whether evidence-based trauma-focused treatments maintain efficacy in the substantial population with co-occurring PTSD and cannabis use, a combination frequently encountered but understudied in RCT populations. Understanding treatment outcomes across cannabis use status is essential for clinicians to make informed decisions about intervention selection and patient stratification in this high-prevalence, high-disability population. The findings could reshape treatment protocols and expectations for individuals with PTSD+SUD who report cannabis use, potentially improving outcomes by tailoring interventions based on empirical rather than assumed treatment response patterns.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 This meta-analysis of individual patient data from trauma-focused treatment trials provides valuable real-world insight into PTSD+SUD populations, though several limitations warrant careful interpretation in clinical practice. The analysis draws from Project Harmony’s rigorous RCT framework, lending credibility to findings about cannabis use patterns during evidence-based PTSD treatment, yet the heterogeneity of included studies, variation in cannabis measurement methods, and the challenge of isolating cannabis effects from concurrent alcohol or polysubstance use complicate straightforward conclusions. Additionally, RCT populations typically exclude more severely dependent or actively using individuals, potentially limiting generalizability to the complex patients seen in routine clinical settings where cannabis use may be serving genuine symptom management functions or representing untreated underlying conditions. The practical takeaway for clinicians is that while evidence-based trauma-focused treatments remain the standard of care for co-occurring PTSD+SUD, explicit screening and non-judgmental discussion about cannabis use patterns during treatment planning can help identify whether use reflects self